Adjunctive glucocorticoid therapy in patients with septic shock.
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Whether hydrocortisone reduces mortality among patients with septic shock is unclear. METHODS: We randomly assigned patients with septic shock who were undergoing mechanical ventilation to receive hydrocortisone (at a dose of 200 mg per day) or placebo for 7 days or until death or discharge from the intensive care unit (ICU), whichever came first. The primary outcome was death from any cause at 90 days. RESULTS: From March 2013 through April 2017, a total of 3800 patients underwent randomization. Status with respect to the primary outcome was ascertained in 3658 patients (1832 of whom had been assigned to the hydrocortisone group and 1826 to the placebo group). At 90 days, 511 patients (27.9%) in the hydrocortisone group and 526 (28.8%) in the placebo group had died (odds ratio, 0.95; 95% confidence interval [CI], 0.82 to 1.10; P=0.50). The effect of the trial regimen was similar in six prespecified subgroups. Patients who had been assigned to receive hydrocortisone had faster resolution of shock than those assigned to the placebo group (median duration, 3 days [interquartile range, 2 to 5] vs. 4 days [interquartile range, 2 to 9]; hazard ratio, 1.32; 95% CI, 1.23 to 1.41; P<0.001). Patients in the hydrocortisone group had a shorter duration of the initial episode of mechanical ventilation than those in the placebo group (median, 6 days [interquartile range, 3 to 18] vs. 7 days [interquartile range, 3 to 24]; hazard ratio, 1.13; 95% CI, 1.05 to 1.22; P<0.001), but taking into account episodes of recurrence of ventilation, there were no significant differences in the number of days alive and free from mechanical ventilation. Fewer patients in the hydrocortisone group than in the placebo group received a blood transfusion (37.0% vs. 41.7%; odds ratio, 0.82; 95% CI, 0.72 to 0.94; P=0.004). There were no significant between-group differences with respect to mortality at 28 days, the rate of recurrence of shock, the number of days alive and out of the ICU, the number of days alive and out of the hospital, the recurrence of mechanical ventilation, the rate of renal-replacement therapy, and the incidence of new-onset bacteremia or fungemia. CONCLUSIONS: Among patients with septic shock undergoing mechanical ventilation, a continuous infusion of hydrocortisone did not result in lower 90-day mortality than placebo. (Funded by the National Health and Medical Research Council of Australia and others; ADRENAL ClinicalTrials.gov number, NCT01448109 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since then, three large RCTs have been published [354, 478, 479].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [479]
In the citing paper
“The optimal dose, timing of initiation, and duration of corticosteroids remain uncertain; recent RCTs used 200 mg per day of IV hydrocortisone in divided doses [354, 479].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [479]
In the citing paper
“The three trials [354, 478, 479] also used different inclusion criteria: in ADRENAL [479] eligible patients were those on any dose of vasopressor or inotrope for ≥ 4 h to maintain a MAP > 60 mmHg, and present at the time of randomisation.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [479]
In the citing paper
“In the ADRENAL [479] study, hydrocortisone was administered for a maximum of seven days or until ICU discharge or death; in APROCCHSS [478] hydrocortisone was administered for seven days; in VANISH [354] 200 mg of hydrocortisone was administered daily for 5 days and then tapered over further 6 days.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [479]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The third international consensus definitions for sepsis and septic shock (Sepsis-3).
Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J.-D., Coopersmith, C. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.0287 · Cited by 28,250
Self-citationA Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
APACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
Bone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
Self-citationFleischmann, C., Scherag, A., Adhikari, N. K. J., Hartog, C. S., Tsaganos, T., Schlattmann, P., Angus, D. C., & Reinhart, K. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201504-0781oc · Cited by 3,548
Annane, D. (2002) · JAMA · doi:10.1001/jama.288.7.862 · Cited by 3,087
The Hypothalamic–Pituitary–Adrenal Axis and Immune-Mediated Inflammation
Chrousos, G. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322008 · Cited by 2,579
Hydrocortisone Therapy for Patients with Septic Shock
Sprung, C. L., Annane, D., Keh, D., Moreno, R., Singer, M., Freivogel, K., Weiss, Y. G., Benbenishty, J., Kalenka, A., Forst, H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa071366 · Cited by 2,132
Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014.
Rhee, C., Dantes, R., Epstein, L., Murphy, D. J., Seymour, C. W., Iwashyna, T. J., Kadri, S. S., Angus, D. C., Danner, R. L., Fiore, A. E., et al. (2017) · JAMA · doi:10.1001/jama.2017.13836 · Cited by 1,884
Cited by
Items 601–700 of 1,000
Complications Associated with Glucocorticoids Treatment in Critically Ill Patients
Confalonieri, P., Reccardini, N., Kette, S., & Salton, F. (2025) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2661-5208 · Cited by 4
Rasheed, M., Khan, Y. H., Mujtaba, G., Mallhi, T. H., Saadullah, M., & Saifullah, A. (2019) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2019-136987 · Cited by 4
McDonnell, E., Collins, R. D., Hernández, M., & Brown, A. R. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220910788 · Cited by 4
“Studies have consistently confirmed the use of HC 200–300mg/day in patients with septic shock results in decreased time to shock reversal compared to placebo.(2,7,9,10,15) The efficacy of MP in the treatment of septic shock is less defined.”
ResultHuang, C., Miles, T. J., Thomas, B., Todd, S., Wilson, C. T., & Suliburk, J. W. (2021) · Injury · doi:10.1016/j.injury.2021.05.036 · Cited by 4
Sardaneh, A. A., Penm, J. H.-D., Oliver, M., Gattas, D. J., McLachlan, A. J., & Patanwala, A. E. (2021) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2021-003035 · Cited by 5
Sepsis and Septic Shock: Evolving Evidence, Evolving Paradigms
Shorr, A. F., & Zilberberg, M. D. (2022) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0041-1740975 · Cited by 5
Lenney, M., Kopp, B. J., & Erstad, B. L. (2022) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxac156 · Cited by 4
Barrett, K. P., & Sweeney, R. M. (2019) · International Anesthesiology Clinics · doi:10.1097/aia.0000000000000227 · Cited by 4
The Role of Vagus Nerve Stimulation in Sepsis
Asad, Z. U. A., Przebinda, A. S., Chaudhary, A. M. D., Farooqui, S. M., Youness, H. A., & Stavrakis, S. (2020) · Bioelectronics in Medicine · doi:10.2217/bem-2020-0010 · Cited by 5
Efficacy and safety of corticosteroids in immunocompetent patients with septic shock
Lu, X., Han, W., Gao, Y., Guo, S., Yu, S., Yu, X., Zhu, H., & Li, Y. W. (2021) · World Journal of Emergency Medicine · doi:10.5847/wjem.j.1920-8642.2021.02.007 · Cited by 6
Immunomodulator use in paediatric severe sepsis and septic shock
Lee, A. O. C. J., Chua, A. H. Y., Sultana, R., Lee, J. H., & Wong, J. J. (2021) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.2021178 · Cited by 4
Rivas, M., Motes, A., Ismail, A., Yang, S., Sotello, D., Arevalo, M., Vutthikraivit, W., Suchartlikitwong, S., Carrasco, C., IWUJI, K. C., et al. (2023) · SAGE Open Medicine · doi:10.1177/20503121221146907 · Cited by 6
Corticosteroids in Adult Cardiac Surgery—Yet Another Paper
Patvardhan, C., & Vuylsteke, A. (2018) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2018.05.009 · Cited by 4
Lemieux, S. M., Levine, A. R., & Gritsenko, D. (2019) · Critical Care Medicine · doi:10.1097/ccm.0000000000003980 · Cited by 5
Host-Directed Adjunctive Therapies in Immunocompromised Patients with Pneumonia
Hensley, M. K., & Cruz, C. S. D. (2024) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2024.10.003 · Cited by 3
Mortality time frame variability in septic shock clinical trials: A systematic review
Laserna, A., Cuenca, J. A., Martin, P., Fowler, C., Correa, J. E. B., Manjappachar, N. K., Fowler, C. S., Lopez-Olivo, M. A., Borges, M., Sprung, C. L., et al. (2025) · Medicina Intensiva · doi:10.1016/j.medine.2025.502172 · Cited by 7
Li, Q., Wang, D., & Fan, H. (2025) · Infection and Drug Resistance · doi:10.2147/idr.s516013 · Cited by 3
“All included predictors were highly significant (p < 0.001), reinforcing their importance in predicting new infections.”
InfluentialSelf-citationMahmoudi, P. S., Sadeghi, F., Saberian, M., Khalili, H., & Shafaati, M. (2026) · Journal of Anesthesia Analgesia and Critical Care · doi:10.1186/s44158-025-00335-x · Cited by 3
Bench-to-Bedside Insights into the Challenges of Immunosuppression in Sepsis
Huang, S., Huang, S., Huang, X., Feng, X., Wang, R., Liu, D., Sun, J., Zhang, H., Du, J., Lin, L., et al. (2026) · Pathogens · doi:10.3390/pathogens15020159 · Cited by 6
“Glucocorticoids possess potent anti-inflammatory effects and have been used as an adjunctive therapy for septic shock for more than four decades, with a favorable safety profile [62].”
Self-citationCurrent status of immunomodulatory therapies in adult sepsis patients: where do we stand?
Papatheodosiou, D., Giamarellos‐Bourboulis, E. J., & Tsoukas, C. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2646192 · Cited by 3
“Two trials assessing hydrocortisone + SoC as opposed to hydrocortisone + fludrocortisone + SoC (adjunctive corticosteroid treatment in patients with septic shock (ADRENAL study) and activated protein C and corticosteroids for human septic shock (APROCCHSS study)) yielded conflicting results [57,58].”
Biletska, O. M., Garyachiy, Y. V., Markovska, O. V., Latohuz, S. I., & Shevchenko, A. S. (2025) · Medicine Today and Tomorrow · doi:10.35339/msz.2025.94.4.bgm · Cited by 4
International multidisciplinary consensus statement on sepsis code guidelines: A Delphi approach
Borges-Sa, M., Giglio, A., Martín‐Loeches, I., Nates, J., del Castillo, J. G., Cardenas, Y., Mergulhão, P., Candel, F. J., Zaragoza, R., Escartín, M. N. L., et al. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70145 · Cited by 4
Wu, J., Huang, M., Wang, Q., Ma, Y., & Jiang, L. (2019) · Hong Kong Journal of Emergency Medicine · doi:10.1177/1024907919833205 · Cited by 4
Hydrocortisone Continuous Infusion Versus Bolus Dose on Glycemic Control in Critically Ill Subjects
Coles, L. L., Forehand, C. C., & Quidley, A. M. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019850937 · Cited by 3
“Six episodes of hyperglycemia were noted in the CI group compared to 3 in the placebo group.(11)”
BackgroundResultLi, Z., Zhang, X., Wu, Y., Xie, C., Liu, C., He, X., Wu, Z., Hua, G., & Li, Y. (2023) · Emergency and Critical Care Medicine · doi:10.1097/ec9.0000000000000072 · Cited by 4
Torbic, H., Bulgarelli, L., Deliberato, R. O., & Duggal, A. (2023) · Journal of Pharmacy Practice · doi:10.1177/08971900231185392 · Cited by 3
“48,49 These fi ndings support the use of steroids in the hyper-in fl ammatory ARDS subphenotype with increased in-fl ammatory markers and hemodynamic instability, since they help accelerate ventilator weaning and reduce ICU length of stay for those patients, especially if pneumonia or shock are also…”
Aldhaeefi, M., Alshaya, A. I., Belrhiti, S., & Rungkitwattanakul, D. “. (2023) · Critical Care Explorations · doi:10.1097/cce.0000000000000940 · Cited by 4
Aspek Farmakologi dan Indikasi Corticosteroid
Setiawan, G., & Suardamana, K. (2023) · Cermin Dunia Kedokteran · doi:10.55175/cdk.v50i11.623 · Cited by 4
John, K. E., Kirkpatrick, M., Aytoda, P., Elefritz, J. L., Palettas, M. S., Rosales, B. N., Murphy, C. V., & Doepker, B. A. (2024) · International Journal of Critical Illness and Injury Science · doi:10.4103/ijciis.ijciis_66_23 · Cited by 3
“[7] A recent large ( n = 88,275), retrospective database study by Bosch et al . found a significant reduction in inhospital death or discharge to hospice (adjusted absolute risk difference, −3.7%; 95% CI: 4.2%–3.1%; P < 0.001) with the addition of fludrocortisone to hydrocortisone for the treatment…”
InfluentialBecker, D., von Röder, M., Wagenhäuser, J., Eichberger, S., Herten, M., & Dudda, M. (2024) · Journal of International Medical Research · doi:10.1177/03000605241290480 · Cited by 4
Immunopharmacological Insights into Cordyceps spp.: Harnessing Therapeutic Potential for Sepsis
Saxena, J., Agarwal, G., Das, S., Kumar, A., Thakkar, K., Kaushik, S., Srivatsava, V. K., Siddiqui, A. J., & Jyoti, A. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128326301240920040036 · Cited by 3
Safety of steroids in severe community-acquired pneumonia
Piedepalumbo, F. V., Motos, A., Blasi, F., & Torres, A. (2025) · European Respiratory Review · doi:10.1183/16000617.0131-2024 · Cited by 6
“…incidence of superinfection, including new episodes of sepsis or septic shock, in patients with sepsis and septic shock who were treated with hydrocortisone, although none of the subsequent trials on corticosteroids in sepsis and septic shock reported a higher risk of superinfection [7, 25, 26].”
Xu, J., Cai, H., & Zheng, X. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-10731-x · Cited by 4
“…no survival benefits or, at best, a slight reduction in mortality with low-dose corticosteroid treatment for septic shock, but patients treated with corticosteroids in both studies experienced significantly shorter times to resolution of shock, cessation of MV and discharge from the ICU [10, 11].”
DeMasi, S. C., Imhoff, B., Lewis, A. A., Seitz, K. P., Driver, B. E., Gibbs, K. W., Ginde, A. A., Trent, S. A., Russell, D. W., Muhs, A. L., et al. (2025) · CHEST Critical Care · doi:10.1016/j.chstcc.2025.100177 · Cited by 4
“…24,28,29,50 the RSI collects physiologic outcomes during the procedure (eg, cardiovascular collapse during intubation), short-term patient-centered outcomes (eg, death by day 28), and long-term patient-centered outcomes (eg, survival and symptoms of posttraumatic stress disorder at 12 months).”
Critical care essentials for pharmacy trainees and new clinical practitioners
Erstad, B. L., Kiser, T. H., & Bauer, S. R. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa417 · Cited by 4
Nadeem, R. N., Elhoufi, A. M., Salama, L., Mahmoud, M., Bon, I., Kamat, S., Elsousi, A. N., Abdalla, R. M., Obaida, Z. A., & Elzeiny, M. G. M. A. (2021) · Dubai Medical Journal · doi:10.1159/000513429 · Cited by 3
Montero, V. R., Ribes, C. M., Montell, M. P., & Zaragoza, R. (2022) · Medicina Intensiva · doi:10.1016/j.medin.2022.03.005 · Cited by 3
Keith, P. D., Bohn, R. I. C., Nguyen, T. C., Scott, L. K., Richmond, M., Day, M. S., Choe, C. H., Perkins, L., Burnside, R. C., Pyke, R., et al. (2024) · Journal of Clinical Apheresis · doi:10.1002/jca.22107 · Cited by 3
Continuous vs Intermittent β-Lactam Antibiotic Infusions for Sepsis—Reply
Dulhunty, J. M., Roberts, J. A., Lipman, J., & BLING III Study Investigators (2024) · JAMA · doi:10.1001/jama.2024.23275 · Cited by 3
Critical illness-related corticosteroid insufficiency: What we know and what we don’t know
Rivas, M., & Sotello, D. (2019) · The Southwest Respiratory and Critical Care Chronicles · doi:10.12746/swrccc.v7i31.595 · Cited by 3
“Finally, a study by Venkatesh et al that compared use of hydrocortisone for 7 days to placebo in septic shock patients also found no survival benefit with the use of steroids; reduction in time for shock resolution and ICU length of stay were the only benefits of steroids in this study.(21) Two major differences betwe…”
ResultEffect of Very Low-Dose Hydrocortisone on Shock Reversal in Patients With Septic Shock
Sbertoli, R., Hu, Z., Henke, J., Wu, E., Santosh, S., Osmon, S., Charbek, E., Jamkhana, Z. A., & Santosh, S. (2020) · Critical Care Explorations · doi:10.1097/cce.0000000000000096 · Cited by 4
Early Clinical Management of Sepsis: Past, Present, and Future
Anyalebechi, J. C., & Coopersmith, C. M. (2022) · Journal of Translational Critical Care Medicine · doi:10.4103/jtccm-d-22-00016 · Cited by 4
Review article: Early steroid administration for traumatic haemorrhagic shock: A systematic review
Hogarty, J., Jones, M. E. B., Jassal, K., Hogarty, D. T., Mitra, B., Udy, A. A., & Fitzgerald, M. (2022) · Emergency Medicine Australasia · doi:10.1111/1742-6723.14129 · Cited by 4
“Recent large multi-centre trials in septic cohorts utilising low dose steroids have demonstrated shortened time to resolution of shock, decreased time on mechanical ventilation and reduced time spent in ICU with no overall difference in mortality.(31) Meta-analyses performed by the Society of Critical Care Medicine an…”
BackgroundCase 37-2022: A 55-Year-Old Man with Fatigue, Weight Loss, and Pulmonary Nodules
Roberts, M. B., Lee, J., Murphy, M. C., Kim, A. Y., Coglianese, E. E., & Hilburn, C. F. (2022) · New England Journal of Medicine · doi:10.1056/nejmcpc2211357 · Cited by 3
Kanjee, Z., Berg, K. M., Bell, T. D., & Reynolds, E. E. (2023) · Annals of Internal Medicine · doi:10.7326/m22-3385 · Cited by 4
Adaptive designs in critical care trials: a simulation study
Li, W., Cornelius, V. R., Finfer, S. R., Venkatesh, B., & Billot, L. (2023) · BMC Medical Research Methodology · doi:10.1186/s12874-023-02049-6 · Cited by 7
Self-citationProfound Vasoplegia after Coronary Artery Bypass Grafting
Chatterjee, S. (2022) · Journal of shock & hemodynamics · doi:10.57905/josh/e2022129 · Cited by 3
Meier, N. F., Munch, M. W., Granholm, A., Perner, A., Hertz, F. B., Venkatesh, B., Hammond, N. E., Li, Q., Bus, L. D., Waele, J. J. D., et al. (2024) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.14419 · Cited by 3
“14,19 This study was performed according to a protocol, which was publicly registered after the primary results of the two studies were known, but before any of the analyses in this study were conducted.”
MethodInfluentialSelf-citationVasopressor Therapy in the Intensive Care Unit
Li, F., & Wimer, D. (2025) · Springer eBooks · doi:10.1007/978-3-031-77335-8_50 · Cited by 3
Peshimam, N., Rodriguez, I., & Nadel, S. (2025) · Springer eBooks · doi:10.1007/978-3-031-64762-8_41 · Cited by 3
Role of angiotensin II in treatment of refractory distributive shock
Rodriguez, R. W., & Fernandez, E. M. (2019) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxy014 · Cited by 3
Reddi, B. A. J. (2020) · Springer eBooks · doi:10.1007/978-3-030-43683-4_17 · Cited by 4
Endocrine interventions in the intensive care unit
Téblick, A., Langouche, L., & den Berghe, G. V. (2021) · Handbook of clinical neurology · doi:10.1016/b978-0-12-819973-2.00028-9 · Cited by 4
Major Publications in the Critical Care Pharmacotherapy Literature: 2020
Bissell, B. D., Campbell, J., Collins, R. D., Cook, C. L., Desai, D., DeWitt, J., Eche, I. M., Eche, I. J., Elsamadisi, P., Juul, J. J., et al. (2021) · Critical Care Explorations · doi:10.1097/cce.0000000000000590 · Cited by 4
Vasopressin in septic shock: what we know and where to next?
Young, P. J., Delaney, A. P., & Venkatesh, B. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05642-w · Cited by 3
Self-citationMøller, M. H., Shankar‐Hari, M., & Alhazzani, W. A. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202005-1984ed · Cited by 3
Hydrocortisone in septic shock: is it worth it?
Young, P. J. (2020) · Critical Care and Resuscitation · doi:10.1016/s1441-2772(23)00385-x · Cited by 3
REMAP-CAP corticosteroids: yet, another swing of the pendulum?
Pirracchio, R., & Sprung, C. L. (2025) · Intensive Care Medicine · doi:10.1007/s00134-025-07957-3 · Cited by 3
Acute management of sepsis beyond 24 hours
Premachandra, A., & Heming, N. (2024) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0044-1787991 · Cited by 2
Reinert, J. P., Becker, K., & Ohlinger, M. J. (2025) · Journal of Pharmacy Technology · doi:10.1177/87551225251320873 · Cited by 3
“3 23-25 Critically, the inconsistent findings across these trials underscore the complexity of sepsis as a syndrome and the multifaceted nature of ascorbic acid and thiamine in modulating its pathophysiology.”
Corticosteroid and antimicrobial therapy in macrolide-resistant pneumococcal pneumonia porcine model
Motos, A., Yang, M., Battaglini, D., Yang, H., Meli, A., Bobí, J., Cabrera, R., Tanzella, G., Vargas, C. R., Arrieta, M., et al. (2025) · Intensive Care Medicine Experimental · doi:10.1186/s40635-025-00731-1 · Cited by 2
“Nonetheless, the precise patient phenotypes that could effectively determine those who would derive the most significant advantages from corticosteroid intervention still need to be fully identified as of current knowledge (5, 13–16).”
Lin, J., Shan, R., Lin, S., & Wu, K. (2025) · British Journal of Hospital Medicine · doi:10.12968/hmed.2024.0814 · Cited by 2
Bastida, C., Lugea, A. E., Fernández-Polo, A., Moreno, F. B., Cerezuela, M. M., Chiva, E. D., García, T. B., García, M. Á. A., González, I., Albanell‐Fernández, M., et al. (2025) · Farmacia Hospitalaria · doi:10.1016/j.farma.2025.05.009 · Cited by 5
Deng, Y., Wang, S., Zhou, S., Zhao, W., Wang, A., & Gao, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1663974 · Cited by 3
Kawazoe, Y., Miyamoto, K., Miyagawa, N., Ohta, Y., Yamamura, H., Kimura, T., Toyoda, Y., Kyo, M., Sato, T., Kinjo, M., et al. (2025) · Critical Care Explorations · doi:10.1097/cce.0000000000001320 · Cited by 6
Miyamoto, K., Kawazoe, Y., Miyagawa, N., Yamamura, H., Ohta, Y., Kimura, T., Toyoda, Y., Kyo, M., Sato, T., Kinjo, M., et al. (2025) · Artificial Organs · doi:10.1111/aor.70025 · Cited by 2
Potential of interleukin-7 in sepsis as a biomarker and therapeutic agent: a narrative review
Zhang, T., Liu, H., Tie, Y.-F., Meng, T., & Liang, Q. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1649049 · Cited by 4
“Moreover, corticosteroids may exacerbate immune dysfunction (19, 20).”
Alshamsi, F. E., Alkaabi, S., Alfadli, M., Alshkeili, N. A. N. S., Alhosani, S. M. I., & Agha, A. (2025) · Diagnostics · doi:10.3390/diagnostics15202588 · Cited by 2
“The ADRENAL trial (n = 3800), the largest study to date, found no mortality benefit at 90 days (27.9% vs. 28.8%, p = 0.50) but demonstrated faster shock reversal with hydrocortisone [25].”
InfluentialRuyuan, L., Zhangshun, S., Li, H., & Jianling, S. (2025) · BMC Anesthesiology · doi:10.1186/s12871-025-03388-1 · Cited by 3
Xiang, Y., Huang, R., Jiang, X., Chen, Q., Luo, C., Wang, H., Jiang, J., Jia, X., Huang, G., Liu, M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1679750 · Cited by 2
Shen, J., Fang, K., Qiu, Y., & Li, L. J. (2025) · European journal of medical research · doi:10.1186/s40001-025-03736-4 · Cited by 2
“Drawing from previous research, the mortality among critically ill patients ranged from 0.28 to 0.46 [43–45]; to adopt a conservative estimate and maximize the required sample size, the p was 0.25.”
InfluentialFyn deficiency drives pro-inflammatory macrophage activation to exacerbate septic acute lung injury
Liu, Y., Xu, B., Zhang, W., Zuo, Y., Fu, T., Lu, X., Xing, X., Geng, Q., Liu, B., Li, N., et al. (2026) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.12.022 · Cited by 2
Chang, W.-H., Hu, T.-Y., & Kuo, L. (2026) · Diagnostics · doi:10.3390/diagnostics16010173 · Cited by 2
“…supportive strategies, including intravenous fluid strategies [30], choice of resuscitation targets (e.g., peripheral perfusion-based approaches versus lactate-driven strategies) [31], corticosteroid regimens [32,33], and vitamin C–based interventions with mixed findings across studies [34–36].”
Liu, S., Shi, P., Jin, Y., Fan, L., Ni, Q., Mao, J., Shao, Z., Du, X., Chen, H., & Fu, M. (2026) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2026.117709 · Cited by 2
Rahman, M. H., Shin, J., & Makhammatjonovich, M. M. (2025) · International Journal of Management and Sustainability · doi:10.18488/11.v14i4.4644 · Cited by 2
“Specifically, ITS was measured using four items from Venkatesh, Morris, Davis, and Davis (2003) and Venkatesh et al. (2018), while a four-item scale for DL was adopted from Jinkyo et al. (2023).”
Hart, S., Smith, S., Nash, B., Stratton, H., Rosengren, P., Goud, R., Tacon, C. L., & Hanson, J. (2026) · Acta Tropica · doi:10.1016/j.actatropica.2026.108154 · Cited by 2
Hyper-inflammation and immunosuppression: redefining sepsis therapy using modern approaches
Prajapati, M., Singh, V., Mishra, A., Khatua, D., Rana, M., & Jyoti, A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1810887 · Cited by 4
“In a severe septic shock patient, the corticosteroid is reserved and is often given due to a high requirement for vasopressors like noradrenaline (1 μg/kg/min) to regulate the arterial blood pressure (Venkatesh et al., 2018).”
Sung, J. J., Digholkar, G., & Pearson, R. M. (2026) · Small · doi:10.1002/smll.74914 · Cited by 2
Sepsis and septic shock - recognize early, act fast, treat right
Bumbaširević, V., Stanisavljević, J., Veličković, J., Hadžibegović, A., Milenković, M., & Ivančević, N. (2020) · Srpski arhiv za celokupno lekarstvo · doi:10.2298/sarh200128040b · Cited by 2
Immunomodulatory and Anti-Inflammatory Properties of Glucocorticoids
Ayroldi, E., Migliorati, G., & Riccardi, C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00052-9 · Cited by 2
Suárez-de-la-Rica, A., Croes, B., Ciudad, L., Vallejo, I., Mújica, J., Díaz‐Almirón, M., & Maseda, E. (2022) · Revista Española de Quimioterapia · doi:10.37201/req/107.2022 · Cited by 3
“The use of corticosteroids has been shown to reverse septic shock [18,19], but only in one trial it was possible to control hydrocortisone administration [15].”
BackgroundBloos, F. (2023) · AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie · doi:10.1055/a-1813-2319 · Cited by 2
“Insbesondere die letzte Funktion dürfte dafür verantwortlich sein, dass Hydrokortison zu einem schnelleren Vasopressor-Weaning führt [18, 19].”
BackgroundInfluentialWhite, K. C., Chaba, A., Meyer, J., Ramanan, M., Tabah, A., Attokaran, A. G., Kumar, A., McCullough, J., Shekar, K., Garrett, P., et al. (2024) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2024.101435 · Cited by 4
Tao, T., Shi, Y., Ye, X., Mi, W., & Lou, J. (2025) · Health Science Reports · doi:10.1002/hsr2.70360 · Cited by 3
“Conversely, the APROCCHSS trial (enrolled 1241 patients) found that patients randomized to GCs exhibited lower 90 ‐ day mortality [10].”
Trends in Critical Care Medicine: Innovations Shaping the Future
Saqib, M. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1010714 · Cited by 2
Park, J. E., Hwang, S. Y., Jo, I. J., Sim, M. S., Cha, W. C., Yoon, H. J., Kim, T. R., Lee, G. T., Kim, H. S., Sohn, I., et al. (2020) · Medicina · doi:10.3390/medicina56010042 · Cited by 4
Cost Analysis of Adjunctive Hydrocortisone Therapy for Septic Shock: U.S. Payer Perspective
Oh, M., Patanwala, A. E., Alkhatib, N. S., Almutairi, A. R., Abraham, I. L., & Erstad, B. L. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004501 · Cited by 2
O uso do corticoide na sepse e no choque séptico: revisão sistemática
Teixeira, L. A. M., Araújo, S. L. S., Santos, J. R. L. D. A., Alves, M. L. M., Oliveira, L. A., de Menezes, L. R. S., Rodrigues, L. M. C. L., & Oliveira, D. M. D. L. (2023) · Brazilian Journal of Development · doi:10.34117/bjdv9n3-135 · Cited by 2
Adadey, S. M., Yakass, M. B., Agyemang, S., & Duodu, S. (2018) · Current Drug Discovery Technologies · doi:10.2174/1570163815666180227162926 · Cited by 2
“In a similar pattern, continuous infusion of hydrocortisone did not lower mortality compared to the placebo [43].”
Intensivmedizinische Studien aus 2017/2018
Reuß, C. J., Bernhard, M. H., Beynon, C., Hecker, A., Jungk, C., Nußhag, C., Weigand, M. A., Michalski, D., & Brenner, T. (2018) · Der Anaesthesist · doi:10.1007/s00101-018-0474-x · Cited by 3
The role of steroids in severe CAP
Nora, D., Nedel, W. L., Lisboa, T. C., Salluh, J. I., & Póvoa, P. M. S. R. (2020) · Hospital Practice · doi:10.1080/21548331.2020.1720215 · Cited by 2
“The ADRENAL trial [115] showed no 90day mortality benefit in patients assigned to hydrocortisone therapy (3658 patients analyzed).”
BackgroundSeptic shock: perspective methods of diagnostics and therapy based on immunopathogenesis
Ильинична, Г. Л. (2020) · Medical Immunology (Russia) · doi:10.15789/1563-0625-ssp-1862 · Cited by 2
Endocrine and Electrolyte Disorders
Inglis, P., Moretti, E. W., & Funk, D. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-56724-4.00040-x · Cited by 2
Ramanan, M., Billot, L., Rajbhandari, D., Myburgh, J., & Venkatesh, B. (2021) · PLoS ONE · doi:10.1371/journal.pone.0255361 · Cited by 3
“Patient randomization data was extracted from the Adjunctive glucocorticoid therapy in patients with septic shock [5] (ADRENAL) screening log and linked to ICU characteristics obtained from the Critical Care Resources registry maintained by Australia New Zealand Intensive Care Society (ANZICS) Centre for Outcome and R…”
MethodSelf-citationEREN, E. E., Dinç, G., Kontaş, O., Alp, E., & Doğanay, M. (2021) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2001-163 · Cited by 2
“However, the effect of steroid treatment on reducing mortality in sepsis is still controversial [3].”
Background24th International Symposium on Infections in the Critically Ill Patient
Artigas, A., Carlet, J. M., Garnacho, J., Niederman, M. S., & Torres, A. (2019) · Medical Sciences · doi:10.3390/medsci7020023 · Cited by 3
Ahmad, S. R., Tarabochia, A. D., Budahn, L., LeMahieu, A., Anderson, B. K., Vashistha, K., Karnatovskaia, L. V., & Gajic, O. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.826169 · Cited by 3
Zhang, W., Chen, T., Chen, H.-J., Chen, N., Xing, Z., & Fu, X.-Y. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i20.4833 · Cited by 2
Han, Y., Bai, X., Wu, S., Luan, X., Ren, L., Wang, J., She, Z., Xiao, B., & Du, G. (2023) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1155/2023/9955105 · Cited by 2
“High doses of glucocorticoid were widely applied during the outbreaks of SARS to suppress lung infammation and immune response; however, it appeared to be associated with side efects [87–89].”
Background
Metadata
- Authors
- Venkatesh, B., Finfer, S., Cohen, J., Rajbhandari, D., Arabi, Y., Bellomo, R., Billot, L., Correa, M., Glass, P., Harward, M., Joyce, C., Li, Q., McArthur, C., Perner, A., Rhodes, A., Thompson, K., Webb, S., & Myburgh, J.
- Affiliations
- The University of Sydney (AU)
- From the George Institute for Global Health, University of New South Wales (B.V., S.F., D.R., L.B., M.C., P.G., M.H., Q.L., K.T., J.M.), St. George Clinical School, St. George Hospital (J.M.), Sydney Medical School, University of Sydney (B.V., S.F., J.M.), and Royal North Shore Hospital (S.F.), Sydney, the Princess Alexandra Hospital (B.V., C.J.) and Royal Brisbane and Women’s Hospital (J.C.), University of Queensland, and the Wesley Hospital (B.V., J.C.), Brisbane, Austin Hospital (R.B.), the...
- University of Copenhagen (DK)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-03
- Volume
- 378
- Issue
- 9
- Pages
- 797-808
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2784412824
- Cited by
- 1,037
- References
- 40
- Citations by year
- 2026: 111 · 2025: 122 · 2024: 90 · 2023: 106 · 2022: 110 · 2021: 121 · 2020: 149 · 2019: 135 · 2018: 91
- FWCI
- 96.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Monash University Research Portal (Monash University) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- St George's Online Research Archive (St George's University of London) (acceptedVersion)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Research Repository (Kingston University London) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Funders
- National Health and Medical Research Council (1004108, 1124926)
- Health Research Council of New Zealand (12/206)
- National Institute of Health Research, United Kingdom
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Keywords
- septic shock, cortisol, mortality, mechanical ventilation, shock resolution, blood transfusion, intensive care unit, sepsis treatment, subgroup analysis, mechanical ventilation duration, vasopressor requirement, glycemic control
- MeSH terms
- Aged, Anti-Inflammatory Agents, Double-Blind Method, Female, Humans, Hydrocortisone, Infusions, Intravenous, Male, Middle Aged, Recurrence, Respiration, Artificial, Shock, Septic, Survival Rate, Fungemia, Bacteremia, Treatment Outcome, Chemotherapy, Adjuvant, Renal Replacement Therapy, APACHE
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.